Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood.

Publication ,  Journal Article
Spellman, S; Hurley, CK; Brady, C; Phillips-Johnson, L; Chow, R; Laughlin, M; McMannis, J; Reems, J-A; Regan, D; Rubinstein, P; Kurtzberg, J ...
Published in: Cytotherapy
August 2011

The following commentary was developed by the National Marrow Donor Program Cord Blood Advisory Group and is intended to provide an overview of umbilical cord blood (UCB) processing, summarize the current state of potency assays used to characterize UCB, and define limitations of the assays and future needs of the cord blood banking and transplant community. The UCB banking industry is eager to participate in the development of standardized assays to uniformly characterize cellular therapy products that are manufactured in a variety of ways. This paper describes the desired qualities of these assays and how the industry proposes to co-operate with developers to bring relevant assays to market. To that end, the National Marrow Donor Program (NMDP) Cord Blood Bank Network is available to serve as a resource for UCB testing material, research and development consulting, and product/assay testing in an accredited UCB manufacturing environment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cytotherapy

DOI

EISSN

1477-2566

Publication Date

August 2011

Volume

13

Issue

7

Start / End Page

848 / 855

Location

England

Related Subject Headings

  • Reproducibility of Results
  • Immunology
  • Humans
  • Fetal Blood
  • Cell Transplantation
  • Blood Banks
  • Biological Assay
  • 3206 Medical biotechnology
  • 3204 Immunology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Spellman, S., Hurley, C. K., Brady, C., Phillips-Johnson, L., Chow, R., Laughlin, M., … National Marrow Donor Program Cord Blood Advisory Group, . (2011). Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy, 13(7), 848–855. https://doi.org/10.3109/14653249.2011.571249
Spellman, Stephen, Carolyn K. Hurley, Colleen Brady, Lisa Phillips-Johnson, Robert Chow, Mary Laughlin, John McMannis, et al. “Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood.Cytotherapy 13, no. 7 (August 2011): 848–55. https://doi.org/10.3109/14653249.2011.571249.
Spellman S, Hurley CK, Brady C, Phillips-Johnson L, Chow R, Laughlin M, et al. Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy. 2011 Aug;13(7):848–55.
Spellman, Stephen, et al. “Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood.Cytotherapy, vol. 13, no. 7, Aug. 2011, pp. 848–55. Pubmed, doi:10.3109/14653249.2011.571249.
Spellman S, Hurley CK, Brady C, Phillips-Johnson L, Chow R, Laughlin M, McMannis J, Reems J-A, Regan D, Rubinstein P, Kurtzberg J, National Marrow Donor Program Cord Blood Advisory Group. Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy. 2011 Aug;13(7):848–855.
Journal cover image

Published In

Cytotherapy

DOI

EISSN

1477-2566

Publication Date

August 2011

Volume

13

Issue

7

Start / End Page

848 / 855

Location

England

Related Subject Headings

  • Reproducibility of Results
  • Immunology
  • Humans
  • Fetal Blood
  • Cell Transplantation
  • Blood Banks
  • Biological Assay
  • 3206 Medical biotechnology
  • 3204 Immunology
  • 1103 Clinical Sciences